Risks and Compliance - The company is subject to various risks including geopolitical tensions, economic sanctions, and weather conditions that could materially affect its operations and financial performance [18]. - The company is exposed to regulatory risks related to greenhouse gas emissions and sustainability disclosures, which could impact its operations and financial results [53]. - The company is required to comply with the Corporate Sustainability Reporting Directive (CSRD) starting from January 1, 2027, which may increase compliance costs [55]. Sustainability Initiatives - The company is actively engaged in sustainability initiatives, including producing renewable feedstocks and developing plant-based protein ingredients [61]. - The company has a non-deforestation commitment established in 2015, implementing programs to prevent deforestation in its supply chains [62]. - Bunge aims for a 25% absolute reduction in Scope 1 and 2 GHG emissions and a 12.3% reduction in Scope 3 emissions by 2030 from a 2020 baseline [75]. - The company has set additional intensity reduction targets by 2026, including a 10% reduction in water usage, waste disposal to landfill, energy consumption, and Scope 1 and 2 emissions, all from a 2016 baseline [73]. - Bunge established Science Based Targets (SBTs) in 2021, verified by the SBTi, focusing on GHG emissions reductions across all three scopes [72]. - Bunge's sustainability strategy includes connecting farmers with end customers to address shared sustainability challenges in food, feed, and fuel supply chains [68]. - Bunge's annual global sustainability report tracks progress towards its sustainability targets and metrics [74]. - The company integrates material sustainability risks into its Enterprise Risk Management (ERM) framework to enhance business resilience against climate-related risks [69]. - Bunge's leadership engages with stakeholders to align on public commitments and quantifiable targets related to sustainability [71]. Workforce and Culture - As of December 31, 2025, Bunge employed approximately 34,000 people, with 43% in South America, 24% in EMEA, 20% in North America, and 13% in Asia-Pacific [76][78]. - The company emphasizes a culture of belonging and inclusion, aiming to attract and retain top talent to meet the evolving needs of a growing world [80]. - The company is committed to enhancing its workplace environment through career development and total rewards programs [77]. Business Operations - The company has minimal research and development activities, focusing instead on product development and process improvements to drive growth [45]. - The company is involved in strategic acquisitions and partnerships to enhance its market position and operational capabilities [18]. - The company’s operations are influenced by seasonal demand fluctuations, particularly in its refined oils and milling businesses [47]. - The company has a diversified global asset network that helps mitigate risks associated with climate change and operational disruptions [59]. - The company’s sustainability function is led by the Executive Vice President, Global Markets and Chief Sustainability Officer, ensuring alignment with sustainability objectives [67].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 001-42140 Lakeside Holding Limited (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorpor ...

Revenue and Customer Base - Gentherm's revenues from its two largest customers, Lear Corporation and Adient plc, were $234 million and $164 million, representing 16% and 11% of total product revenues, respectively[46]. - In 2025, the top two customers, Lear and Adient, accounted for 16% and 11% of product revenues, respectively, while General Motors and Volkswagen each represented 12% of product revenues[63]. - Product revenues by OEM for 2025 show Volkswagen and General Motors at 12%, BMW at 9%, and Ford at 8%, reflecting a competitive landscape[47]. - In 2025, 66% of product revenue was generated from sales to customers outside the United States, including Europe and Asia[85]. - Over 15% of 2025 product revenue was generated from sales to customers in China, amid ongoing U.S.-China trade tensions[86]. Business Segments and Strategy - The company is organized into two reportable segments: Automotive and Medical, focusing on climate and comfort solutions in automotive and patient temperature management in the medical sector[18][19]. - Gentherm's automotive products include Climate Control Seats, Climate Control Interiors, and Lumbar and Massage Comfort Solutions, which are designed to enhance passenger comfort[14][27]. - Gentherm's strategy emphasizes profitable growth, operational excellence, and financial performance, leveraging core technologies to expand into new markets such as home and office, power-sports, and commercial vehicles[36][39]. - The automotive segment represents 97% of product revenues for the years ended December 31, 2025, 2024, and 2023, indicating a strong reliance on the automotive industry[73]. Financial Performance - For the year ended December 31, 2025, product revenues increased by 2.9% to $1,498,602 thousand compared to $1,456,124 thousand in 2024[191]. - Operating income for the year ended December 31, 2025, was $82,700 thousand, a decrease of $24,315 thousand from $107,015 thousand in 2024[191]. - The company reported a net income of $18,285 thousand for 2025, down from $64,947 thousand in 2024, reflecting a decline of $46,662 thousand[191]. - The cost of sales increased to $1,136,426 thousand in 2025 from $1,089,693 thousand in 2024, resulting in a gross margin decrease to $362,176 thousand[191]. - The company’s net research and development expenses rose to $94,759 thousand in 2025, compared to $88,697 thousand in 2024[191]. Operational Challenges - The company is subject to intense competition, particularly from Chinese-based component suppliers, which could impact pricing and margins[62]. - Seasonal fluctuations in automotive vehicle production are expected, particularly during summer and December, affecting operational performance[52]. - The global automotive supply chain has been adversely impacted by raw material shortages and manufacturing disruptions, which are expected to continue affecting profitability[77]. - The company’s ability to manage new product launches effectively is critical, as delays or quality issues could lead to significant financial penalties[70]. Research and Development - The company is committed to research and development, focusing on innovative products and partnerships to enhance energy utilization and production efficiencies[20][21]. - Gentherm's core technologies include thermal management, air moving devices, pneumatic solutions, and advanced valve systems, which are applicable across various end markets[22][23][25][26]. Mergers and Acquisitions - The company is pursuing a Reverse Morris Trust transaction with Modine Manufacturing Company, which involves the transfer of Modine's Performance Technologies business and the merger of SpinCo into Gentherm[16][17]. - The Modine Transaction is subject to conditions including shareholder approval and regulatory approvals, and failure to complete it could adversely impact the market price of the company's Common Stock[131]. - The integration of Performance Technologies following the Modine Transaction may present significant challenges, potentially affecting the combined company's business and financial condition[134]. Risks and Compliance - The company faces risks related to data privacy and security laws, which could lead to significant penalties and operational costs if not complied with[106]. - Regulatory changes, including tariffs and trade policies, could materially affect the company's operations and financial results, particularly in relation to supply chain costs and demand[104]. - The company is subject to extensive regulation in its patient temperature management business, with potential costs associated with compliance and inspections[116]. Capital Structure and Liquidity - As of December 31, 2025, the company's total consolidated indebtedness was $189.1 million, with $307.9 million available for additional borrowings under the Second Amended and Restated Credit Agreement[122]. - The company expects to incur significant one-time costs related to the Modine Transaction, which may include transaction-related fees and expenses, potentially impacting liquidity and cash flows[137]. - The company utilizes strategies to manage global liquidity needs, with $103.1 million in cash and cash equivalents held by non-U.S. subsidiaries as of December 31, 2025[126]. Shareholder Information - Current shareholders will experience substantial dilution in the Merger, with pre-Merger shareholders owning approximately 60% of the issued and outstanding shares of Common Stock on a fully diluted basis post-Merger[141]. - The company has not paid any cash dividends since formation and does not expect to pay any in the foreseeable future[161]. - The company authorized a stock repurchase program of up to $150.0 million over a three-year period, expiring June 30, 2027, with $10.0 million repurchased in 2025[162].

FNF Reports Fourth Quarter and Full Year 2025 Financial Results Jacksonville, Fla. – (February 19, 2026) - Fidelity National Financial, Inc. (NYSE:FNF) (FNF or the Company), a leading provider of title insurance and transaction services to the real estate and mortgage industries and a leading provider of insurance solutions serving retail annuity and life customers and institutional clients through its majority-owned, publicly traded subsidiary F&G Annuities & Life, Inc. (NYSE:FG) (F&G), today reported fina ...

Exhibit 99.1 RingCentral Announces Fourth Quarter and Fiscal Year 2025 Results Total revenue at $2.5 billion, up 5% Operating cash flow of $617 million, up 28% YoY; free cash flow of $530 million, up 32% YoY Initiates quarterly cash dividend of $0.075 per share Increases share repurchase authorization to $500 million "Our 2025 results reflect disciplined execution across growth, profitability, and capital allocation. We expanded GAAP operating margin to 4.8% and non-GAAP operating margin to 22.5%, generated ...

Hospital Operations - As of December 31, 2025, the company operated 104 critical illness recovery hospitals across 28 states, with approximately 37%, 33%, and 32% of revenue from Medicare reimbursement for the years ended December 31, 2023, 2024, and 2025, respectively [22]. - The company operated 1,917 outpatient rehabilitation clinics across 39 states and the District of Columbia as of December 31, 2025 [51]. - The company has a significant presence in the rehabilitation hospital segment, operating 38 rehabilitation hospitals in 15 states as of December 31, 2025 [63]. - As of December 31, 2025, the company operated 104 critical illness recovery hospitals and 38 rehabilitation hospitals, all certified by Medicare [100]. - The company operated 18 critical illness recovery hospitals and 11 rehabilitation hospitals that are treated as provider-based satellites, with 294 outpatient rehabilitation clinics also classified as provider-based [163]. Patient Care and Quality - The average length of stay for patients in critical illness recovery hospitals was 31 days for the year ended December 31, 2025 [24]. - The average length of stay for patients in rehabilitation hospitals was 14 days for the year ended December 31, 2025 [38]. - All rehabilitation hospitals were accredited by TJC and certified by Medicare as inpatient rehabilitation facilities as of December 31, 2025 [39]. - The company focuses on high-quality care and service, utilizing patient satisfaction surveys to continuously improve service levels [55]. - The company maintains quality assurance programs to support and monitor care standards, ensuring compliance with regulatory requirements and Medicare certifications [31]. Financial Performance - Medicare accounted for 28.6% of the company's revenue in 2025, while commercial insurance represented 51.6% [71]. - Revenue from workers' compensation programs accounted for approximately 15% of outpatient rehabilitation segment revenue, 2% of rehabilitation hospital segment revenue, and 1% of critical illness recovery hospital segment revenue for the year ended December 31, 2025 [102]. - The company's revenue sources include Medicare and Medicaid, which generally pay less than customary charges for services provided [73]. - The company employed approximately 45,300 employees, including 30,800 full-time and 14,500 part-time employees [75]. - The company has approximately 17,500 credentialed practitioners providing services in its hospitals [78]. Strategic Growth - The company is pursuing opportunistic acquisitions to grow its network of critical illness recovery hospitals, focusing on improving financial performance through clinical program additions and centralized administrative functions [36]. - The company aims to increase commercial volume by expanding relationships with commercial insurers, offering high-quality, cost-effective care [35]. - The company aims to increase market share by opening new clinics in existing markets and entering joint ventures with hospital systems [56]. - The company is pursuing opportunistic acquisitions to grow its network of rehabilitation facilities and improve financial performance [60]. Regulatory Compliance - The company is required to comply with the Health Insurance Portability and Accountability Act (HIPAA) and has a Privacy and Security Committee to monitor compliance, which has not materially affected its financial condition [169]. - The company must provide clear pricing information online for at least 300 "shoppable services" as mandated by new regulations effective January 1, 2021 [174]. - The Stark Law imposes penalties for prohibited referrals, including civil monetary penalties of up to $15,000 per service and exclusion from federal healthcare programs [162]. - The company is required to monitor government publications to enhance compliance efforts related to fraud and abuse enforcement [159]. - The Compliance and Audit Committee meets quarterly to review compliance program activities and ensure adherence to regulatory requirements [182]. Operational Challenges - The company faces significant operating issues due to shortages of clinical personnel, which may lead to increased use of costly temporary labor [76]. - The company has implemented a communications tool called the "10-Foot Circle of Employee Safety," resulting in significant reductions in workplace injuries [87]. - The company maintains strong community and employee relations, emphasizing quality care and customer service to drive patient volume [59]. Financial Obligations - As of December 31, 2025, Select had outstanding borrowings of $1,039.5 million under a term loan and $100.0 million under a revolving facility, with variable interest rates [444]. - An interest rate cap was entered into on March 31, 2025, limiting the Term SOFR rate to 4.5% on $1.0 billion of principal outstanding under the term loan, applicable through March 31, 2028 [445]. - A 0.25% increase in market interest rates will impact the annual interest expense on variable rate debt by $2.8 million per year [446].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________________ FORM 10-K ____________________________________ ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2025 ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number: 001-36257 TRAVERE THERAPEUTICS, INC. (Exact Name of Registrant as specified in its Charter) Delaware 27-484269 ...

Financial Performance - Fourth quarter 2025 net sales were $633.7 million, a slight increase from $632.2 million in Q3 2025, while full year 2025 net sales reached $2.5 billion, up from $2.2 billion in FY 2024[3][5] - Fourth quarter 2025 reported net income attributable to Century stockholders was $1.8 million, a decrease of $13.1 million sequentially, with full year 2025 net income at $41.8 million, down $295.0 million from FY 2024[4][8] - Adjusted net income for Q4 2025 was $128.2 million, a sequential improvement of $70.3 million, while full year 2025 adjusted net income was $253.8 million, an increase of $152.4 million from FY 2024[4][8] - Total net sales for the three months ended December 31, 2025, were $633.7 million, a slight increase from $632.2 million in the previous quarter and $630.9 million in the same quarter of 2024[17] - Total net sales for the twelve months ended December 31, 2025, reached $2,527.9 million, an increase from $2,220.3 million in 2024, indicating a year-over-year growth of approximately 13.8%[19] - Net income for the twelve months ended December 31, 2025, was $15.8 million, a decrease from $306.7 million in 2024[25] Profitability Metrics - Adjusted EBITDA for Q4 2025 was $170.6 million, a sequential increase of $69.5 million, and for full year 2025, it was $425.1 million, up $180.9 million compared to the previous year[6][9] - Gross profit for the same period was $90.0 million, up from $74.9 million in the previous quarter and $66.3 million in the same quarter of 2024, reflecting a gross margin improvement[17] - Operating income decreased to $40.7 million for the three months ended December 31, 2025, compared to $55.9 million in the previous quarter and $49.3 million in the same quarter of 2024[17] - Gross profit for the twelve months ended December 31, 2025, was $256.4 million, significantly higher than $172.0 million in 2024[19] - Operating income for the twelve months ended December 31, 2025, was $158.1 million, compared to $108.4 million in 2024, reflecting a year-over-year increase of approximately 45.9%[19] Cash and Liquidity - Century's liquidity position at December 31, 2025, included cash and cash equivalents of $134.2 million and total liquidity of $418.0 million[7] - Cash and cash equivalents increased to $134.2 million as of December 31, 2025, compared to $32.9 million as of December 31, 2024[21] - Cash provided by operating activities for 2025 was $183.6 million, a significant improvement from a cash used of $24.6 million in 2024[25] - The company reported a net cash increase of $99.9 million for the year, compared to a decrease of $54.6 million in 2024[27] Production and Shipments - Shipments of primary aluminum in Q4 2025 were 140,257 tonnes, a 14% decrease from Q3 2025, while full year shipments totaled 647,112 tonnes, down 5% from FY 2024[3][7] - Total shipments of primary aluminum for 2025 were 647,112 tonnes, generating sales of $2.2 billion, compared to 677,967 tonnes and $1.9 billion in 2024[29] Strategic Initiatives - The company announced a joint development agreement with Emirates Global Aluminium to build a new smelter in Oklahoma, marking the first new primary aluminum smelter in the U.S. since 1980[5] - The Mt. Holly restart project aims to bring back over 50,000 tonnes of idled production by the end of Q2 2026[5] - The company expects first quarter 2026 adjusted EBITDA to range between $215 million and $235 million, driven by improved metal pricing and regional premiums[10] Expenses and Adjustments - The company incurred a share-based compensation expense of $47.0 million in 2025, significantly higher than $11.3 million in 2024[25] - The unrealized loss on derivative instruments was $62.8 million in 2025, compared to a gain of $5.0 million in 2024[25] - The company incurred a net loss on forward and derivative contracts of $94.7 million, a significant increase from a loss of $2.5 million in the prior year[34] - Share-based compensation expenses rose to $47.0 million in 2025, compared to $15.5 million in 2024, indicating a substantial increase of 203%[34] - The impact of equipment failure at the Iceland casthouse resulted in costs of $46.6 million, which were expected to be covered by business interruption insurance[34] - The company reported a loss on extinguishment of debt amounting to $7.7 million, with no similar expense recorded in the previous year[34] - The lower of cost or NRV inventory adjustment was $10.5 million in 2025, contrasting with a gain of $6.4 million in 2024[34] - The company experienced a bargain purchase gain of $245.9 million in 2024, which was not repeated in 2025, impacting year-over-year comparisons[34] Future Outlook - Future outlook includes addressing operational inefficiencies and potential market expansions, particularly in response to recent equipment failures and natural disasters affecting production[33]

Financial Performance - Net sales for 2024 reached $3,373.0 million, an increase of 11.5% compared to $3,024.0 million in 2023 [248]. - Operating income improved to $188.8 million in 2024, up from $112.2 million in 2023, reflecting a 68.2% increase [248]. - Net income for 2024 was $112.5 million, compared to $65.7 million in 2023, representing a 71.3% growth [248]. - Net income for the year ended December 31, 2025, was $112.5 million, a significant increase from $65.7 million in 2024 and $67.8 million in 2023, reflecting a growth of 71% year-over-year [260]. - Income before income taxes for 2025 was $150.0 million, significantly higher than $88.0 million in 2024, marking an increase of 70.5% [413]. - The total income tax provision for 2025 was $(37.5) million, compared to $(22.3) million in 2024, indicating an increase in tax expenses [415]. Assets and Liabilities - Total current assets increased to $1,261.5 million in 2025 from $1,074.6 million in 2024, marking a 17.4% rise [245]. - Total liabilities rose to $1,738.7 million in 2025, up from $1,666.8 million in 2024, indicating a 4.3% increase [245]. - Stockholders' equity increased to $826.1 million in 2025, compared to $743.1 million in 2024, reflecting an 11.2% growth [245]. - Trade receivables increased to $395.2 million in 2025 from $319.7 million in 2024, representing a growth of 23.6% [313]. - Total inventories rose to $725.2 million in 2025, up from $601.9 million in 2024, marking a 20.5% increase [313]. - Property, plant, and equipment, net decreased slightly to $1,145.2 million in 2025 from $1,161.2 million in 2024, a decline of 1.4% [313]. Cash Flow and Capital Expenditures - Cash flows from operating activities decreased to $111.4 million in 2025 from $167.1 million in 2024, indicating a decline of 33.3% [260]. - Capital expenditures for 2025 were $136.9 million, down from $180.8 million in 2024, representing a reduction of 24.3% [260]. - The company reported a net cash used in investing activities of $77.8 million in 2025, compared to $174.6 million in 2024, showing a decrease of 55.5% [260]. - Cash and cash equivalents increased to $18.4 million in 2025 from $7.0 million in 2024, a significant rise of 162.9% [245]. Debt and Financing - Borrowings under the Revolving Credit Facility amounted to $653.3 million in 2025, with repayments of $631.0 million, indicating active management of debt [260]. - The company issued $500 million in 5.875% Senior Notes in 2025, enhancing its capital structure [260]. - The company redeemed $500.0 million of 4.625% Senior Notes in November 2025 at a redemption price of 100% of the principal amount, funded by proceeds from the new Senior Notes and existing cash [385]. - The interest expense for Senior Notes in 2025 was $50.7 million, an increase from $49.6 million in 2024 [391]. - The company has a future principal payment obligation of $1,072.3 million for its Senior Notes and Revolving Credit Facility as of December 31, 2025 [392]. Inventory and Accounting Changes - The company changed its inventory accounting method from LIFO to weighted average cost, impacting all periods presented in the financial statements [232]. - The company changed its inventory valuation methodology from LIFO to WAC effective January 1, 2025, to improve comparability and reflect the physical flow of goods more accurately [280]. Hedging and Risk Management - The company utilized hedging transactions to mitigate exposure to changes in energy prices and commodity costs [220]. - The company uses derivative instruments to manage commodity price, energy cost, and foreign currency risks, recorded at fair value on the balance sheets [290]. - As of December 31, 2025, the company had derivative contracts for approximately 23.9 million pounds of aluminum to hedge sales for 2026 [221]. - A $0.10/lb decrease in the LME market price of aluminum would have resulted in an unrealized mark-to-market loss of $2.5 million as of December 31, 2025 [222]. - The company is exposed to fluctuating prices of alloying metals, with a $0.10/lb decrease in zinc and copper prices resulting in an unrealized mark-to-market loss of $0.6 million as of December 31, 2025 [223]. Employee Benefits and Compensation - The total expense related to all benefit plans for 2025 is $36.1 million, slightly up from $35.0 million in 2024 [347]. - The pension plans' benefit obligation at the end of 2025 is $36.0 million, up from $30.7 million in 2024, while the OPEB obligation increased to $70.0 million from $64.7 million [336]. - The company recorded a liability of $23.8 million for estimated future payments related to the 2025 Short-Term Incentive Plans [357]. - Non-cash compensation expense for the year ended December 31, 2025, totaled $18.0 million, an increase from $13.8 million in 2024 [367]. Environmental and Remediation Activities - The company’s environmental accruals totaled $17.9 million as of December 31, 2025, reflecting ongoing remediation activities [400]. - The company expects that the implementation and ongoing monitoring of environmental remediation could occur over a period of 30 or more years [400]. Other Financial Metrics - Comprehensive income for 2024 was $118.8 million, compared to $73.1 million in 2023, representing a 62.3% increase [252]. - The total Accumulated Other Comprehensive Income (AOCI) ending balance increased to $26.8 million in 2025 from $20.5 million in 2024, reflecting a growth of 15.9% [403]. - Other income, net for 2025 was reported at $11.3 million, a decrease from $19.5 million in 2024, primarily due to lower gains on business interruption insurance recoveries [410].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 __________________________________________ Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025, or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32601 LIVE NATION ENTERTAINMENT, INC. (Exact name of registrant as specified in its charter) Delawar ...